SCHEMBL1620156

SCHEMBL1620156

COc1cc(C=O)c(F)c2c1OCOC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 2/20 0.40
TSHR P16473 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PRKDC P78527 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.35
GAA P10253 1/20 0.35
ACHE P22303 2/20 0.35
MAPT P10636 2/20 0.35
CYP3A4 P08684 3/20 0.34
ALOX15 P16050 2/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 1/20 0.34
ERN1 O75460 4/20 0.34
TLR2 O60603 1/20 0.33
TLR1 Q15399 1/20 0.33
TLR6 Q9Y2C9 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1620026 0.80 ALDH1A1 (0.42) LMNAHPGDALDH1A1KDM4ETSHR
SCHEMBL13092267 0.80 ACHE (0.37) ALDH1A1SMN1; SMN2ACHECYP3A4ALOX15
SCHEMBL1621090 0.78 ALDH1A1 (0.40) LMNAHPGDALDH1A1KDM4ETSHR
SCHEMBL13085732 0.76 ACHE (0.35) ALDH1A1SMN1; SMN2ACHECYP3A4ALOX15
SCHEMBL1620934 0.75 ALDH1A1 (0.46) LMNAHPGDALDH1A1KDM4ETSHR
SCHEMBL1618900 0.72 ALDH1A1 (0.43) LMNAHPGDALDH1A1KDM4ETSHR
SCHEMBL1620324 0.70 ADRA1A (0.34) LMNAALDH1A1KDM4ETSHRACHE
SCHEMBL1620646 0.70 ALDH1A1 (0.41) LMNAHPGDALDH1A1KDM4ETSHR
SCHEMBL10617861 0.69 LMNA (0.53) LMNAHPGDALDH1A1KDM4ETSHR
SCHEMBL10617236 0.66 LMNA (0.49) LMNAHPGDALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194046-B1 Triazolone derivative EISAI R&D MAN CO LTD (JP) 2012-05-09 EP disclosed
US-8163787-B2 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-24 US disclosed
US-8163787-B2 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-24 US disclosed
US-8163787-B2 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-24 US disclosed
US-20110112109-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2011-05-12 US disclosed
US-20110112109-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2011-05-12 US disclosed
US-20110112109-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2011-05-12 US disclosed
US-7928228-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2011-04-19 US disclosed
US-7928228-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2011-04-19 US disclosed
US-7928228-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2011-04-19 US disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
US-20100190783-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2010-07-29 US disclosed
US-20100190783-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2010-07-29 US disclosed
US-20100190783-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2010-07-29 US disclosed
EP-2194046-A1 Triazolone derivative Eisai R&D Management Co., Ltd. (JP) 2010-06-09 EP disclosed
EP-2000465-A1 TRIAZOLONE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-12-10 EP disclosed
EP-2000465-A1 TRIAZOLONE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-12-10 EP disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190783-A1 TRIAZOLONE DERIVATIVES H1-0, H1-10, H1-2 LMNA 2146/4885HPGD 2619/4885ALDH1A1 701/4885
US-20110112109-A1 TRIAZOLONE DERIVATIVES H1-10, H1-0, H1-2 LMNA 1872/4885HPGD 2304/4885ALDH1A1 905/4885
US-20080015199-A1 Triazolone derivatives F3, F12, F2 LMNA 1245/4885HPGD 1122/4885ALDH1A1 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.